PharmaCyte Biotech (PMCB) files notice of late Form 10-Q under Rule 12b-25

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. filed a notice that it will not meet the original deadline for its Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2025. The company says it needs additional time to prepare and review its financial statements to ensure adequate disclosure, and that this delay could not be avoided without unreasonable effort or expense.

Under Rule 12b-25, PharmaCyte expects to file the Form 10-Q no later than the fifth calendar day after the prescribed due date of December 15, 2025. The company indicates that all other required periodic reports over the past 12 months have been filed and that it does not anticipate any significant change in results of operations from the corresponding period of the prior fiscal year in the upcoming report.

Insights

Equity research analyst

Short administrative delay in PMCB’s 10-Q, with no major changes expected.

PharmaCyte Biotech, Inc. reports that its Form 10-Q for the quarter ended October 31, 2025 will be filed later than the prescribed date of December 15, 2025. The stated reason is the need for additional time to prepare and review financial statements to ensure adequate disclosure, citing that filing on time would require unreasonable effort or expense.

The company invokes Rule 12b-25, committing to file the Form 10-Q within the fifth calendar day after the due date. It also confirms that all other required periodic reports over the past 12 months have been filed and explicitly states it does not anticipate any significant change in results of operations versus the same period last year. This frames the event as a timing and process issue rather than a disclosed shift in the business, though investors may still look for the actual filing to confirm consistency once the report is available.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

Commission File Number: 001-40699

(Check one):	¨   Form 10-K	¨   Form 20-F	¨    Form 11-K	x Form 10-Q	¨   Form 10-D
	¨   Form N-SAR	¨   Form N-CSR

For Period Ended: October 31, 2025

¨   Transition Report on Form 10-K

¨   Transition Report on Form 20-F

¨   Transition Report on Form 11-K

¨   Transition Report on Form 10-Q

¨   Transition Report on Form N-SAR

For the Transition Period Ended: _________________

PART I — REGISTRANT INFORMATION

PHARMACYTE BIOTECH, INC.

(Full Name of Registrant)

(Former Name if Applicable)

3960 Howard Hughes Parkway, Suite 500

Address of Principal Executive Office

Las Vegas, NV 89169

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

x	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
¨	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

The Registrant is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2025 (the “Form 10-Q”) by the prescribed date of December 15, 2025 because the Registrant requires additional time to prepare and review its financial statements to ensure adequate disclosure of the financial information required to be included in the Form 10-Q, which delay could not be eliminated by Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, Registrant will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.  

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

	Carlos Trujillo		(917)		595-2850
	(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
	Yes x   No ¨
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
	Yes ¨   No x

2

PharmaCyte Biotech, Inc.

 (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2025	By: /s/ Joshua N. Silverman
	Joshua N. Silverman
	Chief Executive Officer and President

3

FAQ

Why is PharmaCyte Biotech (PMCB) filing its Form 10-Q late?

PharmaCyte Biotech states it cannot file its Quarterly Report on Form 10-Q for the period ended October 31, 2025 by the December 15, 2025 due date because it needs additional time to prepare and review its financial statements to ensure adequate disclosure of required financial information.

When does PharmaCyte Biotech (PMCB) expect to file the delayed Form 10-Q?

PharmaCyte Biotech indicates that, under Rule 12b-25, it expects to file its Form 10-Q no later than the fifth calendar day following the prescribed due date of December 15, 2025.

Does PharmaCyte Biotech (PMCB) expect major changes in results of operations in the upcoming 10-Q?

No. PharmaCyte Biotech answers that it does not anticipate any significant change in results of operations from the corresponding period of the last fiscal year in the earnings statements that will be included in the delayed Form 10-Q.

Have PharmaCyte Biotech’s (PMCB) other SEC reports been filed on time?

Yes. PharmaCyte Biotech confirms that all other periodic reports required under the Securities Exchange Act of 1934 during the preceding 12 months, or for the shorter period it was required to file, have been filed.

Who signed PharmaCyte Biotech’s (PMCB) notification of late filing?

The notification was signed on behalf of PharmaCyte Biotech, Inc. by Joshua N. Silverman, who is identified as Chief Executive Officer and President.

Who is the contact person listed in PharmaCyte Biotech’s (PMCB) late filing notice?

The notice lists Carlos Trujillo along with the telephone number (917) 595-2850 as the contact for further information.